Combination Therapy

Preliminary Data Released for A Phase II Trial of Sipuleucel-T (Provenge) with Concurrent or Sequential Enzalutamide (Xtandi) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

There will be an abstract presented at the Upcoming (May 31- June 3) American Society of Clinical Oncologist Annual Meeting (ASCO) providing very preliminary data on a clinical trial combing Sipuleucel-T (Provenge) and enzalutamide (Xtandi) in men with metastatic castrate resistant prostate cancer (mCRPC). This rational for conducting this trial is the lack of cross [...]

By Malecare|2020-02-04T10:12:06-05:00May 16th, 2014|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, immunotherapy, Provenge, Uncategorized, vaccines, Xtandi|0 Comments

There is Some Cross Resistance Developed Between Both the First Use of Zytiga and the First Use of Xtandi

On March 4, 2014 I wrote a post “Castrate Resistant Prostate Cancer- What to Do Next” (www.advancedprostatecancer.net/?p=4425). The basic theme of the post was about how difficult it is to know how to sequence the new drugs we have to treat advanced prostate cancer (metastatic castrate resistant prostate cancer aka mCRPC). In the post I [...]

By Malecare|2017-10-19T10:48:32-04:00March 7th, 2014|abiraterone acetate, Advanced Prostate Cancer, Combination Therapy, Cross Resistance, Drugs & Treatments, enzalutamide, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Long-Term Results Confirm Value of Adding Radio Therapy to ADT for Prostate Cancer Survival

There were many very interesting and very important items presented at the recent ASCO GU conference. Over the course of the next week or two I will be systematically reviewing many of these finds that have a direct impact on men with advanced prostate cancer. Today’s review is about how to create better results for [...]

By Malecare|2020-02-04T10:49:23-05:00February 3rd, 2014|Advanced Prostate Cancer, ASCO, Combination Therapy, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

A Caution About Yesterday’s Post About Combining Treatments with Chemotherapy

My post to this blog that was written yesterday indicated that for certain men the early use of chemotherapy (docetaxil) could provide significant life extending benefits, especially for men with very advanced prostate cancer. For the purpose of clarification, in this case early use means in men who are still hormone responsive. Given that chemotherapy [...]

By Malecare|2017-10-19T10:49:09-04:00December 7th, 2013|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, ketoconazole, Uncategorized, Understanding APC, Zytiga|1 Comment

Early Chemotherapy for Men Who Are Still Hormone Responsive – For Some It Might Offer Extra Survival

When I was first diagnosed with metastatic prostate cancer one of the first questions that I asked my doctor was whether it made sense for me to start chemotherapy immediately. I very clearly remember him telling me that there was absolutely no evidence that starting chemotherapy at this early stage would do anything to extend [...]

By Malecare|2013-12-06T23:42:14-05:00December 6th, 2013|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, Hormone Therapy, Prostate Ponderings, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Xofigo – Designed to be Used with the Best Standard of Care Treatments

Most of the newly approved drugs and treatments for men with advanced prostate cancer are designed and approved to be used independently of other advanced prostate cancer treatments, other than with the continuation of standard androgen deprivation therapy (ADT). The newly approved drug, Xofigo, is different. It has been designed to supplement, or actually go [...]

By Malecare|2017-10-19T10:49:34-04:00August 23rd, 2013|Advanced Prostate Cancer, Alpha Emitting Radio Therapy, Alpharadin (radium-223), Chemo Therapy, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, estrogen patches, General Information, Hormone Therapy, ketoconazole, MDV3100, Uncategorized, Understanding APC, Xofigo, Xtandi|0 Comments

Increasing Cost of Treating Men with Advanced Prostate Cancer & Its Effects on the Payers

The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not exist 4 years ago. With the addition of all these new options, so comes the addition of significant economic costs, [...]

By Malecare|2013-07-07T07:02:27-04:00July 7th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), Cabazitaxel, Combination Therapy, Drugs & Treatments, Enzalutamide (MDV-3100), Financial, General Information, How We Live, Insurance, Prostate Ponderings, Research, Uncategorized, Understanding APC, Xofigo, Xtandi, Zytiga|2 Comments

On the Horizon – Many More Novel Drugs for the Treatment of Advanced Prostate Cancer

There have been many potential targets identified for the treatment of advanced prostate cancer. Many of these targets are being actively explored with clinical trials designed to test some inhibitors of the targets. Antisense oligonucleotides (OGX-011) targets clusterin, a chaperone protein and OGX-427 which targets heat-shock protein 27 are among the inhibitors being evaluated. OGX-011 [...]

By Malecare|2017-10-19T10:49:43-04:00June 27th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Combination Therapy, Custirsen, Drugs & Treatments, General Information, On The Horizon, Tasquinimod (TASQ), Uncategorized, Understanding APC|0 Comments

Should Provenge be Used Before or After ADT in Men with Biochemical Prostate Cancer Recurrence?

Sequencing of the various new advanced prostate cancer treatments remains a hot topic in our community. What treatment should come first and will the combination of various treatments be even more effective? These types of questions are constantly buzzing around us and they will continue to as long as we develop new treatments. The only [...]

By Malecare|2020-02-04T11:49:24-05:00May 30th, 2013|Advanced Prostate Cancer, ASCO, Bio Chemical Recurrence, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, Hormone Therapy, Provenge, Uncategorized, Understanding APC|0 Comments

From the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium – News of Provenge

Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced prostate cancer. In the course of the next few days I will be reviewing a number of these that I [...]

By Malecare|2020-02-04T08:56:36-05:00February 14th, 2013|abiraterone acetate, Advanced Prostate Cancer, ASCO, Bio Chemical Recurrence, Combination Therapy, Drugs & Treatments, Hormone Therapy, Research, Uncategorized|0 Comments